ArticleBlood cancer journal2021
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis.Haematologica · 2025Trial
- Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.Annals of hematology · 2024Trial
- Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.Cancer medicine · 2023Trial
- How I Treat: Transplantation for primary immune regulatory diseases and inflammatory disorders.Journal of human immunity · 2026Article
- Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.International journal of cancer · 2026Review
- Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.Cancer · 2026Article
- Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan.International journal of hematology · 2026Article
- JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.Haematologica · 2026Review
- Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases.MedComm · 2026Review
- Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine.International journal of molecular sciences · 2026Article
- A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.Bone marrow transplantation · 2026Article
- Efficacy of Janus kinase inhibitors in the treatment of acute exacerbations of rheumatoid arthritis-associated interstitial lung disease: a retrospective observational case series.Frontiers in immunology · 2026Observational
- Cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report.Case reports in cardiology · 2026Article
- Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.British journal of haematology · 2025Article
- Myelofibrosis: Treatment Options After Ruxolitinib Failure.Current oncology (Toronto, Ont.) · 2025Review
- Article
- Pulmonary Coccidioidomycosis in a Ruxolitinib-Treated Polycythemia Vera Patient: A Case Study and Literature Review.Cureus · 2025Article
- Observational
- Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition.Blood advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Francesca PalandriAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di Ematologia, Bologna, Italia. francesca.palandri@unibo.it.ORCID 0000-0001-8367-5668
Giuseppe Alberto PalumboDepartment of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.ORCID 0000-0003-1859-6319
Elena Maria ElliHematology Division, San Gerardo Hospital, ASST Monza, Monza, Italy.
Nicola PolverelliUnit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.ORCID 0000-0001-6297-9697
Giulia BenevoloDivision of Hematology, Città della Salute e della Scienza Hospital, Torino, Italy.
Bruno MartinoDivision of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy.
Elisabetta AbruzzeseDivision of Hematology, Ospedale S. Eugenio, Roma, Italy.ORCID 0000-0001-5228-6491
Mario TiribelliDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.ORCID 0000-0001-9449-2621
Alessia TieghiDepartment of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Roberto LatagliataDivision of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy.
Francesco CavazziniDivision of Hematology, University of Ferrara, Ferrara, Italy.
Micaela BergamaschiClinic of Hematology, Department of Internal Medicine (DiMI), IRCCS AOU San Martino-IST, Genova, Italy.
Gianni BinottoUnit of Hematology and Clinical Immunology, University of Padova, Padova, Italy.
Monica CrugnolaHaematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Alessandro IsidoriHematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
Giovanni CaocciHematology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.ORCID 0000-0002-6585-5187
Florian HeidelInternal Medicine II, Hematology and Oncology, Friedrich-Schiller-University Medical Center, Jena, Germany.ORCID 0000-0003-2438-1955
Novella PuglieseDepartment of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Napoli, Italy.ORCID 0000-0002-2714-5109
Costanza BosiDivision of Hematology, AUSL di Piacenza, Piacenza, Italy.
Daniela BartolettiAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di Ematologia, Bologna, Italia.ORCID 0000-0003-2036-2896
Giuseppe AuteriAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di Ematologia, Bologna, Italia.
Daniele CattaneoHematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Luigi ScaffidiDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Malgorzata Monica TrawinskaDivision of Hematology, Ospedale S. Eugenio, Roma, Italy.
Rossella StellaDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.ORCID 0000-0003-0565-150X
Fiorella CiantiaDivision of Hematology, AOU Policlinico V. Emanuele, University of Catania, Catania, Italy.
Fabrizio PaneDepartment of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Napoli, Italy.
Antonio CuneoDivision of Hematology, University of Ferrara, Ferrara, Italy.
Mauro KramperaDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.ORCID 0000-0002-7280-2040
Gianpietro SemenzatoUnit of Hematology and Clinical Immunology, University of Padova, Padova, Italy.ORCID 0000-0002-6061-4595
Roberto Massimo LemoliClinic of Hematology, Department of Internal Medicine (DiMI), IRCCS AOU San Martino-IST, Genova, Italy.
Alessandra IurloHematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.ORCID 0000-0002-4401-0812
Nicola VianelliAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di Ematologia, Bologna, Italia.
Michele CavoAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di Ematologia, Bologna, Italia.
Massimo BrecciaDivision of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy.ORCID 0000-0003-1163-6162
Massimiliano BonifacioDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.ORCID 0000-0003-0716-1686
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
HumansJanus KinasesMultivariate AnalysisNitrilesPrimary MyelofibrosisProtein Kinase InhibitorsPyrazolesPyrimidinesRisk FactorsTreatment OutcomeJanus KinasesNitrilesProtein Kinase InhibitorsPyrazolesPyrimidinesruxolitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.